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Bacterial peptide toxins are well known
mediators of pathogenicity. Solecki et al.
show that a peptide toxin from
Staphylococcus aureus, PepA1, has
antibacterial activity and that it can be
transformed from toxic to antibiotic
derivatives. This suggests an innovative
way to use bacterial toxins for good.
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Staphylococcus aureus produces peptide toxins that
it uses to respond to environmental cues. We previ-
ously characterized PepA1, a peptide toxin from
S. aureus, that induces lytic cell death of both bacte-
rial and host cells. That led us to suggest that PepA1
has an antibacterial activity. Here, we demonstrate
that exogenously provided PepA1 has activity
against both Gram-positive and Gram-negative bac-
teria.We also see that PepA1 is significantly hemolyt-
ic, thus limiting its use as an antibacterial agent. To
overcome these limitations, we converted PepA1
into nonhemolytic derivatives. Our most promising
derivative is a cyclic heptapseudopeptide with
inconsequential toxicity to human cells, enhanced
stability in human sera, and sharp antibacterial
activity. Mechanistically, linear and helical PepA1 de-
rivatives form pores at the bacterial and erythrocyte
surfaces, while the cyclic peptide induces bacterial
envelope reorganization, with insignificant action
on the erythrocytes. Our work demonstrates that
bacterial toxins might be an attractive starting point
for antibacterial drug development.
INTRODUCTION
Antimicrobial peptides (AMPs) represent factors produced by
organisms to defend themselves against rivals, for survival and
spread. Plant and animal AMPs are part of their innate immune
defenses. AMPs are also produced by various microorganisms,
including bacteria, termed bacteriocins (Hassan et al., 2012).
AMPs provide advantages to the producer against competing
bacteria in the environment and during infections. To defeat
the invading or competing microorganisms, the AMPs target a
fundamental difference between the membranes from prokary-
otes and eukaryotes (Zasloff, 2002). The exposed surfaces of
bacterial membranes are populated by negatively charged phos-
pholipids, whereas the outer leaflet of plants and animal mem-
branes is composed of neutral lipids. Eukaryotic and prokaryotic
AMPs share common features: they are small, cationic, amphi-
philic or hydrophobic, facilitating their interaction with the nega-
tively charged bacterial membranes on which they form poresChemistry & Biology 22, 3causing leakage of cellular solutes or disruption of membrane
integrity, triggering cell death (Melo et al., 2009).
Various bacteria also produce toxic peptides from toxin-anti-
toxin (TA) modules in response to environmental stimuli,
including persister cell formation, stress resistance, protection
against viral infections, or biofilm formation (Ghafourian et al.,
2013). Type I TA pairs encode hydrophobic toxic peptides,
the synthesis of which is repressed by antisense RNAs during
growth, and they are widely distributed in bacteria (Fozo
et al., 2010; Pinel-Marie et al., 2014). We previously identified
functional type 1 TA systems expressed by S. aureus, a major
human pathogen (Sayed et al., 2011). The RNAs for the toxin
gene and the antitoxin lie on opposite strands, with one RNA
encoding a 30-residue PepA1 toxic peptide, while a convergent
antisense RNA inhibits toxin production by preventing its
synthesis. PepA1 structure was solved by nuclear magnetic
resonance (NMR) and is a long bent, interrupted helix, which
presumably forms pores and alters membrane integrity. In vivo,
PepA1 localizes to the membrane and triggers S. aureus death
(Sayed et al., 2012), but PepA1 can also lyse human erythro-
cytes at similar concentrations. Efforts are under way to
develop modified AMPs as anti-infective agents (Wilmes and
Sahl, 2014). Natural AMPs act rapidly and locally and cannot
be used as therapeutics because of their degradation by prote-
ases. In contrast, chemically modified AMPs, such as cyclic
pseudopeptides containing aza-b3-amino acids, possess
increased stability and activity and are promising antibiotic
candidates (Laurencin et al., 2012). Cyclic lipopeptides are
natural products with antibiotic properties (Schneider et al.,
2014). Derivatives of polymyxins, cyclic cationic lipodecapepti-
des that exhibit low toxicity and potency, are being developed
(Vaara, 2013).
Herein, we report that a hemolytic peptide expressed from
S. aureus, PepA1, is bactericidal. A series of shorter, cyclic,
and modified peptides derived from PepA1 were synthesized
and their antibacterial properties assessed against Escherichia
coli and S. aureus, while their toxicity was assessed on human
erythrocytes. The PepA1 sequence was optimized to eliminate
human cell lysis and enhance bactericidal activity. In the pres-
ence of human serum, the stability of the synthesized peptides
was significantly enhanced. Peptide activities were compared
with Nisin action, a bacteriocin used as a food preservative
against Gram-positive bacteria. Nisin is a 34 amino acid peptide,
which forms pores in membranes, inducing leakage of intracel-
lular contents. A cyclic seven-residue lead compound, Pep11,
possesses 13- and 31-fold higher therapeutic indices than the
parental peptide against S. aureus and E. coli, respectively.29–335, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 329
Table 1. Antibacterial Activity against Gram-Negative and Gram-Positive Bacteria and Toxicity against Human Erythrocytes of PepA1
and a Series of Short, Linear, Cyclic, or Hybrid Pseudopeptides
Peptides Sequences
Human Cells S. aureus E. coli
H50 (mM) MIC (mM) TI H50/MIC MIC (mM) TI H50/MIC
PepA1 H-MLIFVHIIAPVISGCAIAFFS
YWLSRRNTK-NH2
70 8 9 8 9
Pep N-ter H-MLIFVHIIAPVISGC-NH2 ND ND ND ND
Pep
C-ter
H-AIAFFSYWLSRRNTK-NH2 420 150 3 75 6
Pep1 H-FFSYWLSRRNTK-NH2 ND 160 80
Pep2 H-FFSYWLSRRTK-NH2 ND 170 80
Pep3 H-FFSWLSRRTK-NH2 ND 190 95
Pep4 H-FFWLSRRTK-NH2 ND 200 100
Pep5 H-FFWLSRTK-NH2 ND 460 230
Pep6 c(FFWLSRRTK) 5 50 0.1 25 0.2
Pep7 c(FFWSRRTK) 14 30 0.5 13 1
Pep8 c(FFWRRTK) 160 9 18 4 40
Pep9 H-FFWLRR-aza-b3Hyt-K-NH2 ND 100 100
Pep10 c(FFWLRR-aza-b3Hyt-K) 150 25 6 13 12
Pep11 c(FFWRR-aza-b3Hyt-K) 840 7 120 3 280
Control Nisin ND 9 5
TI, therapeutic index; ND, not detectable at the maximal concentration tested (300–900 mM). H50 is the peptide concentration at which half of the eryth-
rocytes are lysed. MIC is the peptide concentration at which bacterial growth is inhibited. 20 mM EDTA was added to Nisin for tests against E. coli.PepA1 insignificant hemolytic activity is comparable with that of
Nisin. Furthermore, cell permeation assays and electronic micro-
scopy indicate that Pep11 reorganizes the bacterial envelope by
forming blisters at the cell surfaces of E. coli and S. aureus.
RESULTS AND DISCUSSION
A Toxic Peptide Produced by S. aureus Is Bactericidal
When expressed, PepA1 accumulates in and destroys the
S. aureus membranes (Sayed et al., 2012). We reasoned that
this peptide might also have antibacterial activity when provided
exogenously. This observation was shown for two other extra-
cellular peptides produced by another S. aureus TA pair (Pinel-
Marie et al., 2014). Interestingly, synthesized PepA1 has activity
against Gram-positive (S. aureus) and -negative (E. coli) bacteria,
possessing an 8-mM minimal inhibitory concentration (MIC)
against each bacterium (Table 1). Human erythrocytes hemoly-
sis, however, was also detected and corresponds to 20% of he-
molysis at the MIC.
Converting a Bacterial Toxin to Nonhemolytic
Antibacterial
In an attempt to reduce PepA1 hemolytic activity, its hydro-
phobic N-terminal domain was removed while the amphiphilic
C terminus region was preserved. The N-terminal (Pep N-ter)
and C-terminal (Pep C-ter) domains of PepA1 were synthesized
and their antibacterial activities tested. Pep N-ter has no activ-
ity against S. aureus or E. coli at concentrations of up to
620 mM, although 20% hemolysis was detected at that con-
centration (Table 1). Pep C-ter, however, has low antibacterial
activity (a 15-fold higher MIC than that of Nisin and PepA1),
and 20% hemolysis was detected at the MIC (150 mM).330 Chemistry & Biology 22, 329–335, March 19, 2015 ª2015 ElsevieHydrophobicity was reduced by removing three amino acids
from the N terminus of Pep C-ter. The resulting 12-mer Pep1
has a similar MIC value to the Pep C-ter. The deletion of
residues AIA considerably reduced Pep1 hemolytic activity
(7% at the highest concentration of 620 mM and 0.5% hemo-
lysis at the MIC of 155 mM). This agrees with observations
indicating that higher peptide hydrophobicity correlates with
stronger hemolysis (Chen et al., 2007; Tachi et al., 2002).
Pep1 MIC against S. aureus and E. coli, however, remained
high, 16 times higher than that of Nisin.
Maximizing peptide antibacterial activity while minimizing
hemolytic activity was achieved through iterative, rational
approaches (McInnes et al., 2000). Pep1 amino acids were incre-
mentally removed to determine their implications in activity and
toxicity. The hydrophilic residues were withdrawn, starting with
asparagine, leading to Pep2, presenting hemolytic and antimi-
crobial activities similar to Pep1. The tyrosine and serine resi-
dues were removed to obtain Pep3 and Pep4, respectively.
Pep1 to Pep4 possess similar activities (Table 1). Antimicrobial
activity is influenced by strand length (Dong et al., 2012) and a
minimum of two positive, hydrophilic, residues plus two hydro-
phobic groups are sufficient for activity (Sundriyal et al., 2008).
One of the three positively charged residues, an arginine, was
removed, leading to Pep5 (Table 1). Pep5 antibacterial effective-
ness is low, with an MIC against S. aureus and E. coli 2-fold
higher than Pep4. Therefore, Pep4 has the shorter sequence re-
taining antibacterial activity with undetectable hemolytic activity.
Enhanced Bactericidal Activity by Peptide Engineering
By converting the native peptide to nonhemolytic derivatives
(Pep1–Pep5), their actions on membranes were modified and
their MICs were enhanced (Table 1). Oneway to improve peptider Ltd All rights reserved
Figure 1. Degradation Kinetics of the Anti-
bacterial Peptides in Human Serum
The amounts and half-lives of the peptides were
determined by HPLC analysis, from 0 to 10 hr
incubations in human serum. Inset: Identities
(signs and color codes) and half-lives of the pep-
tides. The half-life of PepA1 primary peptide was
enhanced up to 800 min (Pep6). The error bars
presented are the mean values of three indepen-
dent experiments.antibacterial activity is to increase their structural stability. The
development of synthetic peptides as antibacterial is limited by
their poor stability in vivo. Cyclization stabilizes bioactive pep-
tides, increasing their resistance to hydrolysis and degradations
while retaining their antibacterial activities (Clark et al., 2005).
Peptide cyclization also reduces flexibility for the constituents
within the ring. As an attempt to increase stability and activity,
Pep4 was cyclized to form Pep6. Remarkably and compared
with Pep5, Pep6 antibacterial activity against S. aureus and
E. coli was increased 10-fold, unfortunately accompanied by
hemolysis (Table 1). Compared with Pep6, Pep7 is one residue
shorter and lacks a leucine residue, which slightly reduced
hemolysis, while antibacterial activity was increased 2-fold
(Table 1). Compared with Pep7, Pep8 is shorter and is missing
a serine residue, being 10-fold less hemolytic and 3-fold
more antibacterial than Pep7 (Table 1). The Pep8 cyclic hepta-
peptide is the most active peptide with all natural amino acids.
This may be due to the spatial constraints of the aliphatic chains
of the residues, which differ between the linear and cyclic
peptides (Dathe et al., 2004). Circular Pep6 has a 4-fold higher
activity than linear Pep4 (despite identical sequences between
Pep4 and Pep6). The increased antimicrobial activity associated
with cyclization was also detected for circular Pep10 when
compared with its linear analog Pep9 (Pep9 and Pep10 have
identical sequences). Hemolysis was increased in both cases.
Cyclization of peptide sequences derived from PepA1 enhances
the antibacterial performance, as reported for other peptides
(Dathe et al., 2004). Relative to linear peptides, cyclic derivatives
bind more strongly to negatively charged membranes and pene-
trate deeper into the lipid bilayer (Mika et al., 2011), indicating
that cyclization enhances antibacterial performance but also
hemolysis.
Another strategy to boost the antibacterial activity of AMPs is
to incorporate modified, unnatural peptides (Laurencin et al.,
2012). Derived from the Pep4 sequence without serine, Pep9
linear pseudopeptide containing an aza-b3-homohydroxythreo-
nine replacing a threonine was synthesized. Compared with
Pep4, the Pep9 pseudopeptide has a 2-fold lower MIC against
S. aureus, but a similar activity against E. coli (Table 1). Impor-Chemistry & Biology 22, 329–335, March 19, 2015tantly, Pep9 does not trigger detectable
human erythrocyte lysis. To increase the
activity and stability of Pep9, it was cy-
clized to form the Pep10 peptide, which
possess 4- and 7-fold lower MICs against
S. aureus and E. coli bacteria, respec-
tively, compared with pep9, while remain-
ing slightly hemolytic. These data areconsistent with observations indicating that cyclization en-
hances antibacterial activities of hexapeptides (Dathe et al.,
2004). To reduce Pep10 hemolytic properties, its leucine was
removed to lower hydrophobicity, leading to Pep11. Compared
with Pep10, Pep11 is 6-fold less hemolytic and possesses a
4-fold higher antibacterial activity against our two model bac-
teria, which represents an activity comparable with that of Nisin
(Table 1). Furthermore, Pep11 was bactericidal at concentra-
tions just above the MIC (8 and 16 mM against E. coli and
S. aureus, respectively) with a therapeutic index beyond 102,
suggesting that Pep11 is a promising antibiotic candidate.
Pep11 has an FFWRR natural sequence pattern, which is pre-
sent discontinuously within the native PepA1 sequence. This
motif is unprecedented within all the peptides inventoried into
the Antimicrobial Peptide Database and could be synthesized
as dimers or trimers to enhance activity.
Elevated Stability of the Cyclic Pseudopeptides in
Human Sera
Amajor limitation for using peptides as affinity reagents, probes,
and therapeutics is their instability in biological fluids. Bacteria
and human cells secrete many peptidases. The rapid peptide
clearance and their unfavorable pharmacokinetics, due to
degradation, restrict their use (Marr et al., 2006). Cyclization
and incorporation of modified peptides enhance their resistance
to degradations (Neveu et al., 2012). Hydrolytic stability of natu-
ral peptide sequences in human serum is improved by optimizing
their sequences and by cyclization (Howell et al., 2014). The
peptides were incubated with human serum up to 10 hr and their
stability analyzed and their half-lives determined by reverse-
phase high-performance liquid chromatography (HPLC) (Fig-
ure 1). As controls, the half-lives of Melittin, a 26-residue linear
peptide increasing cell membrane permeability, and Nisin were
determined, and their half-lives are short (Figure 1). PepA1,
Pep2, and Pep4 linear peptides are unstable in human serum,
half degraded after 2–3 min incubation (Figure 1). Compared
with linear Pep4, Pep6 cyclic form has a 320-fold stabilizing
effect. Serum peptidases digest linear peptides but they have
no activity on cyclic peptides (Wildes andWells, 2010). Chemicalª2015 Elsevier Ltd All rights reserved 331
Figure 2. The Native and Lead Peptides
Permeate the E. coli Outer and Inner Mem-
branes
Concurrent measurements of outer (A) and inner (B)
E. coli membrane permeation assays by PepA1
and Pep11.
(A) Detections of nitrocefin degradation products
triggered by a periplasmic b-lactamase.
(B) Detections of ONPG degradation products
produced by a cytoplasmic b-galactosidase. Pre-
sented are the mean values of three independent
experiments.modifications greatly influence the stability of hexameric pep-
tides in human serum, including cyclization (Nguyen et al.,
2010). Remarkably, the most active peptide from the series,
Pep11, has a 240-fold higher stability in serum than the
PepA1 parental peptide (Figure 1).
Assessing the Mechanisms of Peptide-Induced
Bacterial Killing
The ability of the PepA1 and derived Pep11 peptides to permeate
the E. coli outer and inner membranes was monitored through
chromogenic reporter assays, as described (Junkes et al.,
2011). Nitrocefin is excluded by the E. coli outer membrane, but
peptide-triggered permeability enhancement allows nitrocefin
cleavage by the periplasmic b-lactamases. Inner membrane
permeation wasmonitored using orthonitrophenyl-b-galactoside
(ONPG), which is blocked from cell entry in the strain used, but
whichwill be cleavedby b-galactosidase after cytoplasmaccess.
Linear PepA1 and cyclic Pep11 peptides both permeate the
outer and inner membranes of E. coli, and their bactericidal
activities are comparable (Figure 2). In S. aureus, PepA1 localizes
at the membrane and triggers death (Sayed et al., 2012). PepA1
also permeates both the outer and inner membranes of Gram-332 Chemistry & Biology 22, 329–335, March 19, 2015 ª2015 Elsevier Ltd All rights reservednegative bacteria. Compared with a posi-
tive control polymixin B, PepA1 and
Pep11are lessactiveonmembranes.Con-
cerning theoutermembrane, the detection
of the reporter occurs after 30 s with poly-
mixin B and only after 2–3 min for PepA1
and Pep11. For the inner membrane, the
reporter was detected after 20 min with
polymixin B and after 35–40 min for
PepA1 and Pep11 (Figure 2). Although
structurally different, linear PepA1 and cy-
clic Pep11 have similar efficiencies on
the E. coli membranes that correlate with
the MIC results. The ability of PepA1 and
Pep11 to permeate bacterial membranes
sustains their bactericidal effect as they
both destabilize the inner membrane.
Structural Changes of the Bacterial
and Human Cells Triggered by the
Native and Lead Peptides
Scanning electron microscopy (SEM) was
performed to examine the structuralchanges induced by cyclic Pep11, compared with PepA1, in
E. coli and S. aureus bacteria and human erythrocytes. SEM
micrographs of untreated S. aureus, E. coli, and human cells dis-
played intact surfaces (Figure 3). After incubations with PepA1
sub-MIC, the bacterial cells are damaged, with many burst cells
and their intracellular contents released (Figure 3, PepA1).
Similar results are observed with the erythrocytes, as expected
for a toxin, with significant hemoglobin discharge at low peptide
concentrations (Figure S1). These images are consistent with the
sharp toxicity of PepA1 for both prokaryotic and eukaryotic cells.
Linear peptides can act as detergents and form vesicle-like
membrane structures (Legrand et al., 2011). After incubating
E. coli and S. aureus cells with Pep11 sub-MIC, perturbations
of various shapes were detected on the cell surfaces (Figure 3).
SEM images reveal that Pep11 damages the bacterial enve-
lopes, inducing protruding bubbles, the formation of many
vesicle-like bodies, and minor releases of their intracellular
contents. In Gram-negative cells, outer membrane vesicles can
result from stress conditions induced by peptide integration
into the envelope (McBroom and Kuehn, 2007). The atomic
structure of PepA1 suggests that it triggers pore formation within
membranes (Sayed et al., 2012). Similar SEM images were
Figure 3. Damages of Bacterial and Human Cell Envelopes by PepA1 and Pep11 Revealed by SEM
Micrographs of S. aureus (A–C), E. coli (D–F), and human erythrocytes (G–I). S. aureus or E. coli cells were grown in MH and stopped at the exponential growth
phase (OD600 nm, 0.5, 10
8 cfu/ml). The human RBC in PBS suspension is 3%–4% RBC. The S. aureus or E. coli cells were exposed to sub-MIC of either PepA1
(6 mM against 105 cfu/ml) or Pep11 (6 mM for S. aureus and 2 mM for E. coli, respectively against 105 cfu/ml). The human erythrocytes were exposed to 50 mM of
PepA1 and 160 mM of Pep11. Sub-MIC of Pep11 induces the formation of membrane vesicles on the surfaces of the S. aureus and E. coli cells (arrows). For both
bacteria, PepA1 induces the release of the cytoplasmic content, as with Nisin against S. aureus (upper left panel).collected using Nisin against S. aureus as a positive control (Fig-
ure 3), which similarly forms pores on membranes and induces
cytoplasmic releases (Gupta et al., 2009; Wenzel et al., 2014).
Pep11 damages bacterial cells as the cyclodecapeptide grami-
cidin S, forming blisters and bubbles at the E. coli and
S. aureus surfaces (Hartmann et al., 2010). Gramicidin S inte-
grates into bacterial membranes and causes delocalization of
membrane proteins (Wenzel et al., 2014), suggesting that
Pep11 may act similarly. Pep11 is 12-fold less hemolytic than
PepA1 (Table 1), which was supported by the SEM results,
with PepA1 showing lytic activity for erythrocytes in addition to
bacteria, whereas Pep11 was shown to lyse only bacteria (Fig-
ure 3). Gramicidin S cyclic peptide induces colloid-osmotic he-
molysis on human erythrocytes, membrane lesions followed by
hemoglobin release (Katsu et al., 1988). Elevated concentrations
of cyclic Pep11 trigger the formation of sporadic bumps at the
membranes of very few erythrocytes (Figure 3), with negligible
hemoglobin release at elevated concentrations, comparable
with that of Nisin (Figure S1).
Conclusions
Efficient antibacterial peptides are also commonly toxic to
human cells and degraded by peptidases, which restrict their
clinical uses. In this report, a potent bacterial hemolysinwas con-
verted into an antibacterial, while its toxicity to human erythro-
cytes was negated. A cyclic pseudopeptide with an optimized
FFWRRTK sequence pattern leads to bacterial membrane
permeation, with improved stability in human serum. Cyclic
Pep11 has a reconnected peptide sequence located discontinu-
ously within PepA1 C-ter. These disconnected amino acids,
within PepA1, are relevant for activity. Our strategy could be
applied to various active peptides to define shorter, functionalChemistry & Biology 22, 3bactericidal modules. This report allows envisioning novel anti-
bacterial derived from toxins, with reduced sequences and
costs, for pharmaceutical development.
SIGNIFICANCE
Multidrug-resistant bacteria represent a sharp dilemma for
medicine, generatingconcernaboutantimicrobial strategies.
Discovery and optimization of antibacterial drugs is notori-
ously difficult and has been stalled for years. Over the past
25 years, the challenges for antibacterial discovery have
kept the output of novel drug classes to extraordinarily low
levels. Short AMPs are promising candidates for overcoming
the critical and accelerating problem of bacterial resistance
to the antibiotics currently in use. Toxin-inferred potent anti-
bacterial peptides interactwith andpermeate bacterialmem-
branes and are stable in human body fluids. Future studies
will be aimed at documenting the potential for engineering
short cyclic peptide analogswith improvedactivity in animals
infected with pathogens and will report their actions at the
molecular level. Swapping a toxin into active drugs is an
inspiring novel insight, which may be extended and applied
to the myriad of toxic peptide drugs that are kept in drawers.
EXPERIMENTAL PROCEDURES
The complete experimental procedures are available as Supplemental Infor-
mation accessible online.
Automated Solid-Phase Synthesis
Synthesis of linear peptides and pseudopeptides, including Na-Fmoc-amino
acids, Nb-Fmoc-aza-b3-amino acids, Nb-Fmoc-aza-b3-homohydroxythreo-
nine, was accomplished using our previously described synthesis (Laurencin29–335, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 333
et al., 2009) and a Rink Amide resin (100200 mesh; 0.79 mmol/g), except for
the native peptide PepA1 that we used, H-Rink amide Chem Matrix resin
(0.5 mmol/g). Peptides were synthesized at a 100-mmol scale. Peptides were
assembled on the resin by automated Fmoc synthesis protocols run on a
Liberty-12-channel synthesizer (CEM mWaves).
Peptide Stability in Human Sera
The stability of Nisin, Melittin, and synthetic peptides were tested in vitro, as
described (Laurencin et al., 2012).
Antibacterial Assays
The antibacterial activity of peptide was measured using a standard microdi-
lution assay. Two bacterial species were tested: S. aureus strain Newman
and E. coli strain K12 XL-Blue. Bacterial strains were subcultured in Mueller-
Hinton (MH) broth.
Lytic Activity against Human Erythrocytes
Human blood was collected from the Etablissement Franc¸ais du Sang. Red
blood cells (RBC) were recovered to a final concentration of 3% in PBS buffer.
100 ml of this suspension was mixed with 100 ml of 2-fold serial dilutions of
purified peptide in a microtiter plate with v-bottom, from 1 to 0.004 mg/ml in
PBS buffer. The plates were incubated for 2 hr at 37C. After centrifugation,
the absorbance of the supernatant was measured at 414 nm.
Permeation Assays
E. coli outer and inner membrane permeability was determined using E. coli
strain ML-35p, which is lactose permease deficient.
SEM
Bacterial strains were cultured in MH broth to an optical density (600 nm) of
0.5 corresponding to 108 cfu/ml, a bacterial density necessary for SEM
analysis. RBC were recovered to a final concentration of 3% in PBS, the
same concentration as for the hemolytic assays, a density sufficient for
SEM analysis. Following addition of peptides PepA1 and Pep11, samples
were left for 2 hr at room temperature before centrifugation for SEM
preparation.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and one figure and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2014.12.016.
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